Puretech Health/PRTC

-1.64%
-
1D1W1MYTD1YMAX

About Puretech Health

PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.

Ticker

PRTC

Sector

Healthcare

Trading on

LSE

Industry

Biotechnology & Drugs

CEO

Daphne Zohar

Employees

111

Headquarters

Boston, United States

Puretech Health Metrics

BasicAdvanced
£730.74M
Market cap
-
P/E ratio
-£0.17
EPS
1.16
Beta
-
Dividend rate

What the Analysts think about Puretech Health

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
170.48% upside
High £9.22
Low £3.67
£2.10
Current price
£5.68
Average price target

Puretech Health Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-806.45% profit margin
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
$3.1M
-63.53%
Net income
$-25M
13.64%
Profit margin
-806.45%
211.59%

Puretech Health Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1,160%
QuarterlyAnnual
Q2 22
Q2 23
Q4 23
Actual
-$0.08
-$0.32
-
Expected
-$0.20
$0.03
-$0.20
Surprise
-60%
-1,160%
-
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and LSEG. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Puretech Health stock

Buy or sell Puretech Health stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing